These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 21875141)

  • 1. Insights into molecular basis of cytochrome p450 inhibitory promiscuity of compounds.
    Cheng F; Yu Y; Zhou Y; Shen Z; Xiao W; Liu G; Li W; Lee PW; Tang Y
    J Chem Inf Model; 2011 Oct; 51(10):2482-95. PubMed ID: 21875141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of cytochrome P450 inhibitors and noninhibitors using combined classifiers.
    Cheng F; Yu Y; Shen J; Yang L; Li W; Liu G; Lee PW; Tang Y
    J Chem Inf Model; 2011 May; 51(5):996-1011. PubMed ID: 21491913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harnessing machine learning to predict cytochrome P450 inhibition through molecular properties.
    Zahid H; Tayara H; Chong KT
    Arch Toxicol; 2024 Aug; 98(8):2647-2658. PubMed ID: 38619593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors.
    Nath A; Zientek MA; Burke BJ; Jiang Y; Atkins WM
    Drug Metab Dispos; 2010 Dec; 38(12):2195-203. PubMed ID: 20841376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive models for cytochrome p450 isozymes based on quantitative high throughput screening data.
    Sun H; Veith H; Xia M; Austin CP; Huang R
    J Chem Inf Model; 2011 Oct; 51(10):2474-81. PubMed ID: 21905670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WhichCyp: prediction of cytochromes P450 inhibition.
    Rostkowski M; Spjuth O; Rydberg P
    Bioinformatics; 2013 Aug; 29(16):2051-2. PubMed ID: 23740742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro sulfoxidation of thioether compounds by human cytochrome P450 and flavin-containing monooxygenase isoforms with particular reference to the CYP2C subfamily.
    Usmani KA; Karoly ED; Hodgson E; Rose RL
    Drug Metab Dispos; 2004 Mar; 32(3):333-9. PubMed ID: 14977868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries.
    Veith H; Southall N; Huang R; James T; Fayne D; Artemenko N; Shen M; Inglese J; Austin CP; Lloyd DG; Auld DS
    Nat Biotechnol; 2009 Nov; 27(11):1050-5. PubMed ID: 19855396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Human Cytochrome P450 Inhibition Using a Multitask Deep Autoencoder Neural Network.
    Li X; Xu Y; Lai L; Pei J
    Mol Pharm; 2018 Oct; 15(10):4336-4345. PubMed ID: 29775322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-based models for the isoform specificity of cytochrome P450 3A4, 2D6, and 2C9 substrates.
    Terfloth L; Bienfait B; Gasteiger J
    J Chem Inf Model; 2007; 47(4):1688-701. PubMed ID: 17608404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catalytic versus inhibitory promiscuity in cytochrome P450s: implications for evolution of new function.
    Foti RS; Honaker M; Nath A; Pearson JT; Buttrick B; Isoherranen N; Atkins WM
    Biochemistry; 2011 Apr; 50(13):2387-93. PubMed ID: 21370922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1.
    Bu HZ; Magis L; Knuth K; Teitelbaum P
    Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selectivity of polycyclic inhibitors for human cytochrome P450s 1A1, 1A2, and 1B1.
    Shimada T; Yamazaki H; Foroozesh M; Hopkins NE; Alworth WL; Guengerich FP
    Chem Res Toxicol; 1998 Sep; 11(9):1048-56. PubMed ID: 9760279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
    Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
    Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights on cytochrome p450 enzymes and inhibitors obtained through QSAR studies.
    Sridhar J; Liu J; Foroozesh M; Stevens CL
    Molecules; 2012 Aug; 17(8):9283-305. PubMed ID: 22864238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
    Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates.
    Cohen LH; Remley MJ; Raunig D; Vaz AD
    Drug Metab Dispos; 2003 Aug; 31(8):1005-15. PubMed ID: 12867489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the selectivity of In vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities.
    Hickman D; Wang JP; Wang Y; Unadkat JD
    Drug Metab Dispos; 1998 Mar; 26(3):207-15. PubMed ID: 9492382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism of 5-methylchrysene and 6-methylchrysene by human hepatic and pulmonary cytochrome P450 enzymes.
    Koehl W; Amin S; Staretz ME; Ueng YF; Yamazaki H; Tateishi T; Guengerich FP; Hecht SS
    Cancer Res; 1996 Jan; 56(2):316-24. PubMed ID: 8542586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput mass spectrometric cytochrome P450 inhibition screening.
    Lim KB; Ozbal CC; Kassel DB
    Methods Mol Biol; 2013; 987():25-50. PubMed ID: 23475665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.